Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TSC-101

Cell therapy (TCR-T) · Kills target cells, directed at HA-2 minor histocompatibility antigen · developed by TScan Therapeutics

Phase 3 Most advanced trial
TCRX Developer
2 Registered trials

What is TSC-101?

TSC-101 is a preparation of donor-derived T-lymphocytes engineered to express a T-cell receptor specific for the HLA-A*02:01-restricted minor histocompatibility antigen HA-2. The cells recognize HA-2 on tumor cells and mediate cytotoxic T-lymphocyte elimination of them. It is studied in acute myeloid leukemia and myelodysplastic syndromes after haploidentical hematopoietic cell transplantation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (TCR-T)
Targets
HA-2 minor histocompatibility antigen (antigen)
Mechanism
Kills target cells, directed at HA-2 minor histocompatibility antigen
Therapy area
Hematology, Oncology
Developer
TScan Therapeutics, Inc. (TCRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07702578 Phase 3 AML Active not recruiting TCRX
NCT05473910 Phase 1 AML Active not recruiting TCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AMLMDS

More from TScan Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TCRX page.

Follow TCRX, the company behind TSC-101

See TCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TCRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.